TGFB1 and aneurysm: When individuals are diagnosed with subclinical TAAs, routine monitoring begins, and attempts are made to slow aneurysm progression with β blockers (anti-hypertensives) or angiotensin II type I receptor blockers (anti-hypertensives with indirect TGFβ inhibition).